Ipca Labs expects its US generics sales to touch $200 million soon

Ipca Laboratories, after resolving regulatory hurdles and integrating Unichem, is set to re-enter the US generics market aiming for $200 million in revenue within 12-18 months. The focus is on commercializing existing products after an import ban by the US FDA was lifted. Unichem has shown profits following these efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5h9bpUH
via IFTTT